Standards & Regulation

Can certain buzzwords really sway public perceptions of a new drug?

Grant Lindman is director of Eli Lilly’s global anticounterfeiting operations and is passionate about fighting fake medicines.

Recently, Tim Mackey and colleagues examined the extent to which counterfeit drugs had penetrated global legitimate supply chains.

Regulators are driving serialization and tamper-evident packaging initiatives, but is the pharma industry fully primed to defend against counterfeits?

The EMA fights to reinstate its former executive director – and the FDA’s new leader is still unconfirmed

Expedited regulatory approvals bring medicines to market faster – but are they the right drugs?

Dissecting a ligand into smaller fragments can provide a strategy for analyzing the role of key functional groups in a protein-ligand interaction.

It is well established that the use of nanotechnology in medicine and more specifically drug delivery is spreading rapidly.

Abusers are finding ways to circumvent current abuse-deterrent measures, leaving companies in need of new strategies.

Lawrence (Larry) Lesko is a bioanalytical veteran with many years of academic and FDA experience under his belt.